2024 Viral Hepatitis National Progress Report

The Viral Hepatitis National Progress Report provides information on progress toward 2025 goals for new viral hepatitis infections and viral hepatitisrelated deaths, overall and for key populations.

Ten objective indicators assess progress toward achieving key viral hepatitis goals. Select the indicator from the table below for more information.

Check-mark on green, indicating "Met or exceeded current annual target"

Met or exceeded current annual target

Arrow on yellow, indicating "not met, moved toward annual target"

Moving toward annual target, but annual target was not fully met

X on red, indicating "Not met, no change or moved away from annual target"

Annual target was not met and has not changed or moved away  from annual target

Seven standardized viral hepatitis indicators
Baseline
2017 data year
2022 Observed
(Annual target*)
2025 Goal
2023 data year
Trend 2022 Status
Hepatitis A
Reduce estimated new hepatitis A virus infections by ≥40% 6,700 4,500
(4,450)
4,000 micro trend line, depicting trends toward, inline, or away from target X on red, indicating 'Not met—no change or moved away from annual target'
Hepatitis B
Reduce estimated new hepatitis B virus infections by ≥20% 22,200 13,800
(18,700)
18,000 micro trend line, depicting trends toward, inline, or away from target Check on Green, indicating 'Met or exceeded current annual target'
Reduce reported rate of new hepatitis B virus infections among persons who inject drugs by ≥25% 1.4 0.6
(1.1)
1.0 micro trend line, depicting trends toward, inline, or away from target Check on Green, indicating 'Met or exceeded current annual target'
Reduce reported rate of hepatitis B-related deaths by ≥20% 0.46 0.44
(0.39)
0.37 micro trend line, depicting trends toward, inline, or away from target X on red, indicating 'Not met—no change or moved away from annual target'
Reduce reported rate of hepatitis B-related deaths among non-Hispanic Asian/Pacific Islander persons by ≥25% 2.45 2.30
(1.94)
1.84 micro trend line, depicting trends toward, inline, or away from target X on red, indicating 'Not met—no change or moved away from annual target'
Hepatitis C
Reduce estimated new hepatitis C virus infections by ≥20% 44,700 67,400
(36,617)
35,000 micro trend line, depicting trends toward, inline, or away from target X on red, indicating 'Not met—no change or moved away from annual target'
Reduce reported rate of new hepatitis C virus infections among persons who inject drugs by ≥25% 2.3 2.7
(1.8)
1.7 micro trend line, depicting trends toward, inline, or away from target X on red, indicating 'Not met—no change or moved away from annual target'
Reduce reported rate of hepatitis C-related deaths by ≥20% 4.13 2.89
(3.19)
3.00 micro trend line, depicting trends toward, inline, or away from target Check on Green, indicating 'Met or exceeded current annual target'
Reduce reported rate of hepatitis C-related deaths among non-Hispanic American Indian/Alaska Native persons by ≥30% 10.24 9.08
(7.68)
7.17 micro trend line, depicting trends toward, inline, or away from target X on red, indicating 'Not met—no change or moved away from annual target'
Reduce reported rate of hepatitis C-related deaths among non-Hispanic Black persons by ≥30% 7.03 4.75
(5.27)
4.92 micro trend line, depicting trends toward, inline, or away from target Check on Green, indicating 'Met or exceeded current annual target'
* Annual targets assume a constant (linear) rate of change from the observed baseline (2017) to the 2025 goal (2023 data year).
† The number of estimated viral hepatitis infections was determined by multiplying the number of reported cases by a factor that adjusted for underascertainment and underreporting (CDC 2022 Viral Hepatitis Surveillance Report and Klevens et al., 2014).
‡ Per 100,000 population.
¶ Persons aged 18–40 years were used as a proxy for persons who inject drugs.

2024 Report Findings Overview

Summary of findings from the 2024 Viral Hepatitis National Progress Report

View summary of findings

Related Content

National Progress Report Goals

Reduce estimated new hepatitis A virus infections by 40% or more

Reduce estimated new hepatitis B virus infections by 20% or more

Reduce reported rate of new hepatitis B virus infections among persons who inject drugs by 25% or more

Reduce reported rate of hepatitis B-related deaths by 20% or more

Reduce reported rate of hepatitis B-related deaths among Asian and Pacific Islander persons by 25% or more

Reduce estimated new hepatitis C virus infections by 20% or more

Reduce reported rate of new hepatitis C virus infections among persons who inject drugs by 25% or more

Reduce reported rate of hepatitis C-related deaths by 20% or more

Reduce reported rate of hepatitis C-related deaths among American Indian and Alaska Native persons by 30% or more

Reduce reported rate of hepatitis C-related deaths among non-Hispanic Black persons by 30%
or more